VectivBio Publishes Invitation to the Annual General Meeting
May 10 2023 - 8:59AM
VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage
biopharmaceutical company pioneering novel transformational
treatments for severe rare conditions, today published the
invitation to the 2023 Annual General Meeting, which will be held
on Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT at
Memox (meeting room "Small Space"), Elisabethenstrasse 15, 4051
Basel, Switzerland.
Shareholders entered in the company's share
register with the right to vote as of May 2, 2023, at 10:00 p.m.
CEST / 4:00 p.m. EDT will be entitled to participate in the 2023
Annual General Meeting. Shareholders may also be represented at the
2023 Annual General Meeting by the independent proxy or their
proxy, who does not need to be a shareholder, by completing and
signing a proxy form. Such proxy form can be downloaded on the
Computershare portal alongside the admission ticket. For further
information on how to attend the 2023 Annual General Meeting, to
exercise rights, to issue voting instructions to the independent
proxy or to grant proxy, shareholders can access the invitation to
the 2023 Annual General Meeting at www.edocumentview.com/VECT.
About
VectivBio AG
VectivBio (Nasdaq: VECT) is a global
clinical-stage biotechnology company focused on transforming the
lives of patients with severe rare conditions. Our lead product
candidate is apraglutide, a next-generation, long-acting synthetic
GLP-2 analog being developed for a range of rare gastrointestinal
diseases where GLP-2 can play a central role in addressing disease
pathophysiology, including short bowel syndrome with intestinal
failure (SBS-IF) and acute Graft-versus-Host Disease (aGVHD).
VectivBio is also advancing its modular, small
molecule CoMET platform to address a broad range of previously
undruggable Inherited Metabolic Diseases (IMDs). Candidates from
the CoMET platform are initially being evaluated in methylmalonic
acidemia (MMA), propionic acidemia (PA), and other organic
acidemias.
Learn more at www.vectivbio.com, and follow us
on LinkedIn and Twitter.
Forward Looking Statements:
Forward-looking statements are statements that
are not historical facts. Words and phrases such as “anticipated,”
“forward,” “will,” “would,” “may,” “remain,” “potential,”
“prepare,” “expected,” “believe,” “plan,” “near future,” “belief,”
“guidance,” and similar expressions are intended to identify
forward-looking statements. These statements include, but are not
limited to, statements concerning the timing of the 2023 Annual
General Meeting. Such statements are subject to risks and
uncertainties, many of which are difficult to predict and generally
beyond VectivBio’s control, that could cause actual results to
differ materially from those expressed in, or implied or projected
by, the forward-looking statements. Such risks and uncertainties
include, but are not limited to those risks and uncertainties
identified in the “Risk Factors” section of VectivBio’s Annual
Report on Form 20-F filed with the Securities and Exchange
Commission on April 19, 2023 and its other subsequent filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Except to the extent required by law,
VectivBio undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contact:
Patrick MalloySVP, Investor Relations
Patrick.Malloy@vectivbio.com
VectivBio (NASDAQ:VECT)
Historical Stock Chart
From Apr 2024 to May 2024
VectivBio (NASDAQ:VECT)
Historical Stock Chart
From May 2023 to May 2024